Key result
Targeted aptamer proteomics identified 14 novel serum biomarkers that demonstrated moderate-to-high discriminative ability for cardiac allograft vasculopathy (AUC 0.72 to 0.94).
Why the study?
Non-invasive evaluation of cardiac allograft vasculopathy is challenging, and there is currently no validated biomarker for its diagnosis or prognostication.
Does targeted aptamer proteomics identify novel biomarkers for cardiac allograft vasculopathy in heart transplant patients?
Observational (n=31)
Does targeted aptamer proteomics identify novel biomarkers for cardiac allograft vasculopathy in heart transplant patients?
Effect estimate: AUC 0.72 to 0.94
Targeted aptamer proteomics identified 14 novel candidate biomarkers with moderate-to-high discriminative ability for cardiac allograft vasculopathy.
No takes yet. Share an insight, caveat, or question.
Candidate CAV biomarkers show promise for non-invasive detection; leaves open validation and clinical utility in prospective studies.
Almufleh et al. (2019) conducted an observational in Cardiac allograft vasculopathy (n=31). Cardiac allograft vasculopathy (mild-moderate or severe) vs. Normal control (CAV 0) was evaluated on Discriminative ability of identified protein biomarkers for CAV (AUC 0.72 to 0.94). Targeted aptamer proteomics identified 14 novel serum biomarkers that demonstrated moderate-to-high discriminative ability for cardiac allograft vasculopathy (AUC 0.72 to 0.94).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: